Photo Credit: byakkaya
The following is a summary of “A potential inflammatory biomarker for advanced endometrial cancer treated with lenvatinib plus pembrolizumab,” published in the December 2024 issue of Obstetrics and Gynecology by Yanazume et al.
In patients with advanced or recurrent endometrial cancer, inflammatory biomarkers like the neutrophil-to-lymphocyte ratio (NLR) may help predict their response to treatment with lenvatinib (LEN) and pembrolizumab (PEM).
Researchers conducted a retrospective study to identify potential biomarkers that could predict how well patients with advanced or recurrent endometrial cancer respond to LEN plus PEM.
They included 25 patients with advanced or recurrent endometrial cancer who had received LEN and PEM (August 2018 and March 2024). Neutrophil counts, lymphocyte counts, and NLR were compared from endometrial liquid-based cytology (LBC) and peripheral blood samples taken before treatment. These markers were analyzed as predictors for OR, disease control, and progression-free survival (PFS) using receiver operating characteristic (ROC) curves, log-rank tests, and multivariate analysis.
The results showed that although neutrophil counts and NLR in endometrial LBC before initial treatment were effective predictors for OR, the most accurate predictor for PFS was the NLR score in peripheral blood before treatment (0.722, 95% CI: 0.45–0.99, sensitivity: 57.1%, specificity: 94.4%). Patients with a lower NLR (NLR < 5.39) in peripheral blood before treatment had longer PFS than those with a higher NLR (5.39 ≤ NLR; P=0.023, median survival: 13.5 vs. 3.0 months). The lower NLR group also correlated independently with PFS (HR = 2.571; 95% CI = 0.857–7.719; P=0.092).
They concluded that NLR in peripheral blood before treatment may serve as a predictor of PFS in patients with advanced or recurrent endometrial cancer treated with LEN and PEM.
Source: obgyn.onlinelibrary.wiley.com/doi/full/10.1111/jog.16182
